What is Taliglucerase Alfa
Taliglucerase alfa is an enzyme used in the treatment of patients with Gaucher’s disease.
Taliglucerase alfa replaces the endogenous enzyme beta-glucocerebrosidase.
Taliglucerase alfa is produced by recombinant DNA technology using plant cell culture (carrot), making it the first plant-made pharmaceutical.
This process is beneficial because it eliminates the threat of viruses and other pathogens that can contaminate mammalian stocks.
Taliglucerase differs from the endogenous metabolic enzyme by two amino acids at the N terminal and up to 7 amino acids at the C terminal.
Treatment with taliglucerase alfa is indicated for adults and children >= 4 years with a confirmed diagnosis of Type I Gaucher’s disease. The FDA approved taliglucerase alfa under orphan status in May 2012.
Brand Name
ELELYSO
Indications
- Gaucher disease
For replacement therapy of glucosylceramidase in confirmed (type 1) Gaucher disease
Side Effects
- abdominal pain
- anaphylactoid reactions
- angioedema
- antibody formation
- arthralgia
- back pain
- cough
- diarrhea
- dizziness
- erythema
- fatigue
- flushing
- headache
- hypotension
- infusion-related reactions
- nausea
- pruritus
- rash
- throat irritation
- urticaria
- vomiting
- wheezing
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- breast-feeding
- children
- infants
- infusion-related reactions
- neonates
- pregnancy
Interactions
There are no drug interactions associated with Taliglucerase Alfa products.
